Prostate Cancer Disparities throughout the Cancer Control Continuum

Meghan Borysova,Dawood Sultan,Ganna Chornokur,Kyle Dalton,Adewale Troutman

doi:10.3390/socsci2040247

Meghan Borysova, Dawood Sultan + Show 3 more

Open Access

https://doi.org/10.3390/socsci2040247

Copy DOI

Journal: Social Sciences	Publication Date: Nov 8, 2013
Citations: 109	License type: CC BY 4.0

Affiliation: University of South Florida, Florida College

Abstract

Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the United States. The American Cancer Society estimates that 238,590 U.S. men will develop PCa and 29,720 men will die from the disease in 2013. PCa exhibits the most profound racial disparities of all cancers with African American men having a 70% higher incidence rate and more than two times higher mortality rate than Caucasian men. Published research on PCa disparities focuses on singular outcomes such as incidence, mortality or quality of life. The objective of this paper is to provide a comprehensive summary of the racial disparities found at each stage of the PCa Care Continuum which includes prevention, detection, treatments, and outcomes and survival. It focuses primarily on disparities among Caucasian (white) and African American men.

Highlights

The American Cancer Society estimates that 238,590 men in the United States (US) will develop prostate cancer (PCa) in 2013 and 29,720 men will die from the disease in the same year [1]
The review outlined disparities in prevention, detection, treatment, outcomes and survival, and how these disparities are linked to PCa mortality
It reported research findings which revealed that black men were younger at the time of PCa diagnosis, and that they were more likely to present at clinic with higher Prostate Specific Antigen (PSA) values, larger tumor volumes, more aggressive PCa disease, and higher rates of biochemical relapse than white men

Summary

Introduction

The American Cancer Society estimates that 238,590 men in the United States (US) will develop prostate cancer (PCa) in 2013 and 29,720 men will die from the disease in the same year [1]. These estimates indicate that in 2013 PCa will account for 28% of all expected new cancer diagnoses and. The cancer control continuum is a conceptual model through which we can think about the phases of cancer clinical care. This continuum differs from commonly utilized Tumor, lymph Nodes and Metastasis (TNM) cancer staging system which addresses the cellular features and severity of an individual’s cancer and may serve as a prognostic indicator

Objectives

Methods

Findings

Conclusion